Increased sensitivity of the antiestrogen-resistant MCF-7/LY2 human breast carcinoma cell line to apoptosis induced by the novel microtubule stabilizing agent (+)-discodermolide

Breast Journal

Volumn 4, Issue 6, 1998, Pages 409-419

  Balachandran, Raghavan ^a   Grant, Stephen G ^a   Welsh, Manda J ^a   Day, Billy W ^a,b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

(+) discodermolide; Apoptosis; Flow cytometry; Paclitaxel; Pulsed field gel electrophoresis

Indexed keywords

ANTIESTROGEN; DISCODERMOLIDE; DNA FRAGMENT; ESTROGEN RECEPTOR; PACLITAXEL; STABILIZING AGENT; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DRUG RESISTANCE; DRUG STRUCTURE; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROTUBULE;

EID: 0032417609     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.1998.460409.x     Document Type: Article

References (40)

1. Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48:794-847.
2. van Oosterom AT. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol 1995;22:22-28.
3. ter Haar E, Rosenkranz HS, Hamel E, Day BW. Computational and molecular modeling evaluation of the structural basis for tubulin polymerization inhibition by colchicine site agents. Bioorg Med Chem 1996;4:1659-71.
4. ter Haar E, Day BW, Rosenkranz HS. Direct tubulin polymerization perturbation contributes significantly to the induction of micronuclei in vivo. Mutat Res 1996;350:331-37.
5. Gunasekera SP, Gunasekera M, Longley RE, Schulte GK. Discodermolide - a new bioactive polyhydroxylated lactone from the marine sponge Discodermia dissoluta. J Org Chem 1990;55:4912-15. Correction: J Org Chem 1991;56:1346.
6. ter Haar E, Kowalski RJ, Hamel E, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996;35:423-30.
7. Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol®) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997;52:613-22.
8. Balachandran R, ter Haar E, Welsh MJ, Grant SG, Day BW. The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells -preliminary comparisons to paclitaxel. Anticancer Drugs 1998;9:67-76 (erratum: 369-70).
9. Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst Monogr 1993;15:141-47.
10. Csoka K, Dhar S, Fridborg H, Larsson R, Nygren P. Differential activity of Cremophor EL and paclitaxel in patients' tumor cells and human carcinoma cell lines in vitro. Cancer 1997;79:1225-33.
11. Bronzert DA, Greene GL, Lippman ME. Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 1985;117:1409-17.
12. ter Haar E, Day BW. Cytostatic and cytotoxic action of the antitumor agent Z-1,1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines. Anticancer Res 1996; 16:1107-15.
13. Davidson NE, Bronzert DA, Chambon P, Gelmann EP, Lippman ME. Use of two MCF-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. Cancer Res 1986;46:1904-8.
14. Read LD, Snider CE, Miller JS, Greene GL, Katzenel-lenbogen BS. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 1988;2:263-71.
15. Cavailles V, Augereau P, Garcia M, Rochefort H. Estrogens and growth factors induce the mRNA of the 52K-procathepsin-D secreted by breast cancer cells. Nucleic Acids Res 1988;16:1903-19.
16. Neri C, Berthois Y, Schatz B, Drieu K, Martin PM. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer cell sublines. Breast Cancer Res Treat 1990;15:85-93.
17. Mullick A, Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res 1990;50:333-38.
18. Claussner A, Nedelec L, Nique F, Philibert D, Van Teutsch G, de Velde P. 11 beta-amidoalkyl estradiols, a new series of pure antiestrogens. J Steroid Biochem Mol Biol 1992;41:609-14.
19. Strobl JS, Peterson VA. Tamoxifen-resistant human breast cancer cell growth: inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13. J Pharmacol Exp Therapeut 1992;263:186-93.
20. Strobl JS, Peterson VA, Woodfork KA. A survey of human breast cancer sensitivity to growth inhibition by calmodulin antagonists in tissue culture. Biochem Pharmacol 1994;47: 2157-61.
21. Gottardis MM, Lamph WW, Shalinsky DR, Wellstein A, Heyman RA. The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 1996;38:85-96.
22. McCotter D, van den Berg HW, Boylan M, McKibben B. Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro. Cancer Lett 1996;99:239-45.
23. Adler ID, Kliesch U, van Hummelen P, Kirsch-Volders M. Mouse micronucleus tests with known and suspect spindle poisons: results from two laboratories. Mutagenesis 1991;6:47-53.
24. Ritke MK, Rusnak JM, Lazo JS, et al. Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. Mol Pharmacol 1994;46:605-11.
25. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells applicable for gel electrophoresis and flow cytometry. Cytometry 1992;13:795-808.
26. Longley RE, Gunasekera SP, Faherty D, McLane J, Dumont F. Immunosuppression by discodermolide. Ann NY Acad Sci 1993;696:94-107.
27. Hung DT, Nerenberg JB, Schreiber SL. Distinct binding and cellular properties of synthetic (+)- and (-)-discodermolides. Chem Biol 1994;1:67-71.
28. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
29. Oberhammer F, Wilson JW, Dive C, et al. Apoptotic cell death in epithelial cells: cleavage of DNA to 300 and/or 50 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J 1993;12:3679-84.
30. Rusnak JM, Calmels TPG, Hoyt DG, Kondo Y, Yalowich JC, Lazo JS. Genesis of discrete higher order DNA fragments in apoptotic human prostatic carcinoma cells. Mol Pharmacol 1996;49:244-52.
31. ter Haar E, Hamel E, Balachandran R, Day BW. Cellular targets of the anti-breast cancer agent Z-1,1-dichloro-2,3-diphenylcyclopropane: type II estrogen binding sites and tubulin. Anticancer Res 1997;17:1861-69.
32. Nerenberg JB, Hung DT, Somers PK, Schreiber SL. Total synthesis of the immunosuppressive agent (-)-discodermolide. J Am Chem Soc 1993;115:12621-22.
33. Smith AB III, Qiu Y, Jones DR, Kobayashi K. Total synthesis of (-)-discodermolide. J Am Chem Soc 1995;117: 12011-12.
34. Hung DT, Nerenberg JB, Schreiber SL. Synthesis of discodermolides useful for investigating microtubule binding and stabilization. J Am Chem Soc 1996;118:11054-80.
35. 1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telophase. Cancer Res 1994;54:4355-61.
36. Hung DT, Chen J, Schreiber SL. (+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol 1996;3:287-93.
37. Nishio K, Arioka H, Ishida T, et al. Enhanced interaction between tubulin and microtubule-associated protein 2 via inhibition of MAP kinase and cdc2 kinase by paclitaxel. Int J Cancer 1995;63:688-93.
38. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-55.
39. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
40. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-54.